Clinical Trial

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.
Protocol Amendment History 3 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-17
notable Primary completion pushed: 2026-11 -> 2026-12 2026-07-17
minor Completion pushed: 2026-11 -> 2026-12 2026-07-17
Trial Details
NCT Number NCT06982859
Lead Sponsor Eli Lilly and Company
Conditions Diabetes Mellitus, Insulin Sensitivity
Enrollment 95 participants
Start Date 2025-06-02
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-16